Biopharmaceutical company Sirnaomics Ltd., together with its subsidiaries (stock code: 2257), announced on Thursday that it has dosed the first subject in a phase one clinical trial of STP122G for anticoagulation treatment.
The product is part of the Group's GalAhead Factor XI RNAi therapeutic programme that has applications across a wide range of disease indications such as the potential prevention and treatment of stroke after atrial fibrillation, cancer subjects after immunotherapy and improving total knee replacement recovery.
The trial, a phase I, single-centre, randomised, double-blind, sequential cohort study, is to assess the safety, tolerability, Pharmacokinetics and Pharmacodynamics of a single ascending dose of STP122G when administered subcutaneously to healthy subjects.
The safety and tolerability are to be compared among five different doses of STP122G (25mg, 50mg, 100mg, 200mg, 400mg) to select one for future studies. The study is planning to hire a total of 40 participants.
Merck's sotatercept gains priority review for PAH treatment
Antibe gains approval for otenaproxesul PK/PD study
Calliditas Therapeutics' setanaxib receives US FDA orphan drug designation
Everads Therapy signs license, collaboration and supply agreement with Kriya Therapeutics
IDEAYA Biosciences' IDE161 receives US FDA fast track designation
YS Biopharma enrols first subject in Phase three PIKA Rabies Vaccine clinical trial
Armata Pharmaceuticals doses first patient in Phase 2a of AP-SA02 diSArm study
Melt Pharmaceuticals enters exclusive agreement with Catalent for Zydis fast-dissolve tech
EXACT Therapeutics' ACTIVATE trial shows promise in enhancing chemotherapy efficacy
Sanofi granted Priority Review for EoE treatment in young children
Pierre Fabre Laboratories signs long-term collaboration with Vernalis (R&D)
BioArctic and Eisai secure approval for LEQEMBI infusion in Japan for Alzheimer's disease treatment